 1. Primary Research Question What are the rates of complete response CR, partial response PR, progression free survival PFS and overall survival OS in adult patients newly diagnosed with Peripheral T-Cell Lymphoma PTCL who are treated with alemtuzumab given in combination with CHOP cyclophosphamide, doxorubicin, vincristine and prednisolone and ESHAP etoposide, methylprednisolone, cisplatin, cytosine arabinoside administered as an up-front treatment? 